HGF及其c-MET受体在非小细胞肺癌中的研究进展  

Research Progress on HGF and c-MET Receptor in Nonsmall Cell Lung Cancer

作　　者：乔洪源[1] 陈建新[1] 余宗阳[1] 欧阳学农[1] 

机构地区：[1]南京军区福州总医院,福建福州350025

出　　处：《中国肿瘤》2014年第2期141-147,共7页China Cancer

基　　金：国家自然科学基金(81274002)

摘　　要：随着肿瘤分子生物学的飞速发展,分子靶向治疗已成为目前晚期肺癌治疗方法中最具前景的研究领域,因此分子靶点的研究也早已成为医学界关注的热点。近年来,研究发现HGF及其c-MET受体与非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生、发展、组织学类型及预后密切相关。全文就HGF及其c-MET受体的结构、功能及其相关的靶向药物在NSCLC中的研究进展进行综述。With the rapid development of tumor molecular biology, molecular targeted therapy has been the most promising area of research in the treatment of advanced lung cancer,so molecular targets also has become the focus of attention in the medical profession. In recent years,re- searchers found that HGF and c-MET receptor are associated with the occurrence, development, histological type and prognosis of non-small cell lung cancer（NSCLC）. In this paper, the structure, function and correlative targeted drugs of HGF and c-MET receptor in NSCLC were comprehen- sively reviewed.

关 键 词：HGF C-MET 非小细胞肺癌 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]